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Abstract
Background: A high rate of post-infectious fatigue and abdominal symptoms two years after a
waterborne outbreak of giardiasis in Bergen, Norway in 2004 has previously been reported. The
aim of this report was to identify risk factors associated with such manifestations.
Methods: All laboratory confirmed cases of giardiasis (n = 1262) during the outbreak in Bergen in
2004 received a postal questionnaire two years a f t e r .  D e g r e e  o f  p o s t -infectious abdominal
symptoms and fatigue, as well as previous abdominal problems, was recorded. In the statistical
analyses number of treatment courses, treatment refractory infection, delayed education and sick
leave were used as indices of protracted and severe Giardia infection. Age, gender, previous
abdominal problems and symptoms during infection were also analysed as possible risk factors.
Simple and multiple ordinal logistic regression models were used for the analyses.
Results: The response rate was 81% (1017/1262), 64% were women and median age was 31 years
(range 3-93), compared to 61% women and 30 years (range 2-93) among all 1262 cases. Factors in
multiple regression analysis significantly associated with abdominal symptoms two years after
infection were: More than one treatment course, treatment refractory infection, delayed
education, bloating and female gender. Abdominal problems prior to Giardia infection were not
associated with post-infectious abdominal symptoms. More than one treatment course, delayed
education, sick leave more than 2 weeks, and malaise at the time of infection, were significantly
associated with fatigue in the multiple regression analysis, as were increasing age and previous
abdominal problems.
Conclusion: Protracted and severe giardiasis seemed to be a risk factor for post-infectious fatigue
and abdominal symptoms two years after clearing the Giardia infection.
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Background
The intestinal protozoan Giardia duodenalis is a common
cause of waterborne outbreaks in western countries since
the cysts are relatively resistant to water treatment, and in
most developing countries the parasite is highly endemic
[1,2]. The clinical impact of Giardia infection ranges from
mild self-limiting disease to life-threatening malnutrition
[3-5].
Post-infectious complications have been described in chil-
dren in developing countries, where giardiasis contributes
to malnutrition and growth retardation with later risk for
impaired cognitive function [6].
Also post-giardiasis complications in a western country
have recently been described. We reported a high level of
post-infectious fatigue (41%) and abdominal symptoms
(38%) among 1017 cases two years after a waterborne
outbreak in Bergen, Norway in 2004 [7,8]. The aim of this
study was to investigate risk factors associated with such
manifestations.
Methods
Study site and participants
Inclusion criteria was laboratory verified Giardia infection
from the Bergen outbreak. All Giardia-positive cases diag-
nosed by stool microscopy (formalin-ether concentra-
tion) and/or antigen-test (ImmunoCard STAT!
Cryptosporidium/Giardia  rapid assay; Meridian Bio-
science) at the local parasitology laboratory in Bergen
were registered in the period from October 2004 to June
2005, and an additional 16 cases considered to be related
to the outbreak were registered until December 2005. The
majority of cases was registered in November 2004 (n =
863). A higher number than normal was registered also in
2005 (n = 172) after the water supply in December 2004
was considered free from Giardia cysts, probably due to
protracted or secondary infections. A few cases known not
to be infected in Bergen were excluded. According to this,
a study population of 1262 cases, later referred to as "all
cases", was defined.
The investigating laboratory is the only parasitology labo-
ratory in the region, and prior to the outbreak about 50
cases a year were diagnosed, mainly infected abroad [9].
Questionnaire
In August 2006, two years after the peak of the outbreak,
a questionnaire was mailed to all cases, followed by an
additional letter to non-respondents one month later.
We asked about abdominal problems prior to giardiasis;
among these if abdominal problems had ever led to any
of the following: Hospitalisation, sick leave, use of medi-
cation, seeing a doctor or problems without seeking
health care, or if they did not have abdominal problems
prior to September 2004.
Cases were asked about the following symptoms during
giardiasis: Diarrhoea, abdominal pain, weight loss,
malaise, nausea, foul smell and bloating. They were also
asked about sick leave (0, <1, 1, 1-2 or >2 weeks), delayed
education (0, <1, 1 or > 1 semester), time before abdomi-
nal symptoms disappeared (< 1, 1-3, 4-6 or 7-18 months)
and number of treatment courses before abdominal
symptoms ceased (0, 1, 2, >2, or recovered during treat-
ment but relapsed).
We also asked if they had present problems with abdom-
inal symptoms and with fatigue. The results for these latter
questions have been published previously [8]. Present
symptoms including nausea, bloating, abdominal pain,
diarrhoea, constipation and reduced appetite were
recorded on a scale from 0 (no symptoms) to 10 (severe
symptoms). These questions have previously been used in
recording severity of symptoms in patients with irritable
bowel syndrome (IBS) [10].
Number of cases working/studying was estimated as cases
answering the questions concerning sick leave/delayed
education, minus cases answering that they were not
working/studying.
Abdominal symptoms were reported as "no", "unsure" or
"yes" on the question "Do you have abdominal symp-
toms now that you did not have prior to the Giardia infec-
tion?" Fatigue was reported as "less or same as usual",
"more than usual" or "much more than usual" on the
question "Do you have problems with fatigue?" These
were used as ordinal response variables in the statistical
analyses.
Characteristics evaluated as possible risk factors
Whether protracted and severe Giardia infection could be
associated with post-infectious fatigue or abdominal
symptoms was studied, and number of treatment courses,
delayed education and sick leave were all used as indices
of protracted and severe infection in the statistical analy-
ses. A sub-cohort of treatment resistant cases with mean
symptom duration seven months, who had all been suc-
cessfully treated in our out patient clinic, was also
included in the statistical analyses. The characteristics and
results from treatment of this cohort has been published
previously [11]. Age, gender, previous abdominal prob-
lems and symptoms during infection were also evaluated
as possible risk factors.
Statistical methods
For each of the two ordinal response variables at two years
follow-up, fatigue and abdominal symptoms, the possibleBMC Infectious Diseases 2009, 9:206 http://www.biomedcentral.com/1471-2334/9/206
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risk factors were analysed as explanatory variables using
ordinal logistic regression with the proportional odds
model. In the proportional odds model the results are
expressed as the ratio of the odds for a response above a
certain level in the exposed to the odds for a response
above this level in the unexposed. This odds ratio (OR) is
modelled to be independent of the chosen level. First, for
each of the response variables, simple ordinal logistic
regression analysis was done for all risk factors. Then, all
factors were included in a multiple ordinal logistic regres-
sion analysis (proportional odds model) [12]. From the
analyses, unadjusted and adjusted odds ratios were esti-
mated. To avoid loosing cases in the multiple regression
analyses, missing values were included as valid categories
in some variables as follows: "Not recovered" was
included in the variable "Treatment courses", "Not work-
ing" in "Sick leave" and "Not a student" in "Delayed edu-
cation". To evaluate the possible risk that these variables
only reflect the response variables, the multiple regression
analyses were performed with and without each of them.
Age and gender were included into all models with no
regards to significance. The final model included all vari-
ables with p < 0.05 (likelihood ratio test). Statistical anal-
yses were performed using SPSS 15.0 or STATA.
Ethics
Written informed consent was obtained. The regional eth-
ics committee and the Privacy Ombudsman for Research
approved the data collection and analyses of the study.
Results
Patient characteristics
Patient characteristics are shown in Table 1. The response
rate was 81% (1017/1262), later referred to as "respond-
ents". Median age among respondents was 31 years (range
3-93) and 64% were women, compared to 30 years (range
2-93) and 61% among all cases. Among the respondents,
722 (71%) were estimated to be working and 460 (45%)
to be students. Prior to the Giardia  outbreak, 12% of
respondents (124/1017) had visited a doctor due to
abdominal problems, 10% (98/1017) had had abdomi-
nal symptoms without seeking health care, 4% (42/1017)
had used medication for such symptoms, 2% (19/1017)
had been hospitalised and 2% (19/1017) had been on
sick leave due to abdominal problems prior to the Giardia
outbreak. A majority of 71% (718/1017) reported to have
had no previous abdominal problems.
Abdominal symptoms and fatigue two years after infec-
tion was recorded from 38% (389/1017) and 41% (419/
1017) respectively as previously reported [8] (Table 2).
Bloating was the symptom reported to be most severe
(Table 2).
Giardia infection
Symptoms during Giardia infection, as reported two years
later are shown in Table 3. Less than four weeks duration
of symptoms, irrespective of treatment, was recorded in
18%. Only 1% became well without medication. Sick
leave was reported by 46%, and almost half of these had
been on sick leave for more than two weeks. Delayed edu-
cation was reported in 33%, and 17% had one or more
semester delay.
Factors associated with fatigue and abdominal symptoms
The analyses of risk factors associated with abdominal
symptoms and fatigue are presented in Table 4 and 5,
respectively.
Table 1: Age and gender of the respondents and non-
respondents to a postal questionnaire compared to all Giardia-
positive cases during an outbreak in Bergen, Norway in 2004.
Characteristic Respondents
N (%)
Non-respondents
N (%)
All cases
N (%)
Total 1017 (100) 245 (100) 1262 (100)
Gender
Female 647 (64) 117 (48) 764 (61)
Male 370 (36) 128 (52) 498 (39)
Age (Years)
0-19a 62 (6) 25 (10) 87 (7)
20-39 679 (67) 185 (76) 864 (68)
40-59 211 (21) 32 (13) 243 (19)
60-79 55 (5) 3 (1) 58 (5)
80-100 10 (1) 0 (0) 10 (1)
aAmong respondents, 13 cases (1%) were less than 5 years, 13 cases 
(1%) were 5-9 years, 12 (1%) cases were 10-14 years and 24 (2%) 
cases were 15-19 years old.
Table 2: Symptoms two years after Giardia infection in Bergen, 
Norway in 2004, among 1017 respondents to a questionnaire.
Symptoms Casesa (%) Symptom scoreb
Mean ± SEMc Median
Fatigue
Less or same as usual 511 (50)
More than usual 306 (30)
Much more than usual 113 (11)
Abdominal symptoms
No 360 (35)
Unsure 228 (22)
Yes 389 (38)
Bloating 475 (47) 4.57 ± 0.13 5.00
Diarrhoea 467 (46) 3.80 ± 0.12 3.74
Abdominal pain 442 (43) 3.64 ± 0.13 3.00
Nausea 416 (41) 2.23 ± 0.12 2.00
Reduced appetite 398 (39) 1.60 ± 0.12 0.67
Constipation 398 (39) 1.57 ± 0.12 0.66
a Number of persons reporting the symptoms. Percent of 
respondents (n = 1017).
b Symptoms scored from 0 (no symptoms) to 10 (severe symptoms).
c Standard error of the mean.BMC Infectious Diseases 2009, 9:206 http://www.biomedcentral.com/1471-2334/9/206
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More than one course of treatment for giardiasis, as well
as delayed education, was significantly associated with
both fatigue and abdominal symptoms in all analyses.
Previous abdominal problems were not significantly asso-
ciated with post-infectious abdominal symptoms in any
analyses.
Female gender turned out not to be significantly associ-
ated with abdominal symptoms when the variable "treat-
ment courses" was left out from the multiple regression
analysis (data not shown).
Discussion
We have previously reported a high prevalence of fatigue
(41%, 419/1017) and abdominal symptoms (38%, 389/
1017), and a highly significant association between these
symptoms, two years after the Bergen outbreak [8]. In this
study we report an association between protracted and
severe Giardia infection and such symptoms.
Fatigue has been described following Q-fever, Epstein Barr
virus infection, Ross River virus infection, brucellosis,
Lyme disease, viral meningitis and Dengue fever, and in
the first three of these, severe infection was a risk factor
[13-16].
In a sub-cohort of referred cases after the Bergen outbreak,
81% (66/82) fulfilled the Rome II criteria for IBS [17].
Post-infectious (PI)-IBS has been reported with a median
prevalence of around 10% following gastroenteritis of var-
ious aetiology; Campylobacter [18-20], Salmonella [21-23],
Shigella [24-26], Escherichia coli [20] and Trichinella spiralis
[27], and severe infection was the most important risk fac-
tor in these reports [24,28-30].
A possible weakness in our definition of indices of pro-
tracted and severe Giardia infection is that sick leave or
delayed education may be signs of PI-IBS or fatigue rather
than protracted infection or inflammation. Particularly
those reporting ">1 semester delayed education", but also
"sick leave > 2 weeks", could potentially be cases actually
reporting persistent symptoms, but excluding them from
the statistical analyses would have created a selection bias.
More than one treatment course is a reliable index of per-
sistent infection and the finding of this as a highly signif-
icant risk factor in all analyses supports the hypothesis
that protracted and severe infection may cause post-infec-
tious complications. However, some patients may not
have had stool samples tested between the courses, and
may therefore have experienced post-infectious com-
plaints rather than protracted infection. Results regarding
the sub-cohort of referred treatment refractory cases must
be interpreted with caution due to the very low sample
size (n = 29) [11].
If our findings are causal, then the surprisingly high level
of fatigue and abdominal symptoms reported, may have
two possible explanations: A substantial number of cases
had protracted infection due to delayed treatment
explained by late detection of the outbreak [7], and/or the
infection caused inflammation in a high number of cases,
also after clearing the parasites [31]. Giardiasis may cause
damage to the intestinal epithelial brush border, villous
atrophy and inflammation [32]. In duodenal biopsies
from a sub-cohort of 124 cases with symptoms for 8
months (mean) from the Bergen outbreak, inflammation
was found in 47% [31], which is surprisingly high com-
pared to a previous report of duodenal inflammation in
4% of 462 Giardia cases from Germany [33]. This supports
that protracted Giardia infection, and possibly protracted
intestinal inflammation, may have induced PI-IBS and
fatigue in this cohort. Low-grade inflammation in gut-
mucosa has been described as a possible mechanism for
IBS also following other infections [34].
The high prevalence of inflammation in this outbreak
may be explained by immunological host factors, but
probably also by parasite virulence factors. Studies
addressing the possible association between Giardia geno-
Table 3: Distribution of factors during Giardia infection among 
1017 cases in Bergen, Norway in 2004, reported two years later.
Factors during Giardia infection Cases (%)
Symptoms
Diarrhoea 904 (89)
Malaise 761 (75)
Abdominal pain 689 (68)
Bloating 657 (65)
Nausea 647 (64)
Foul smell 612 (60)
Weight loss 539 (53)
None of these symptoms 15 (2)
Duration of abdominal symptoms
< 4 weeks 185 (18)
1-3 months 193 (19)
4-6 months 88 (9)
7-18 months 62 (6)
Number of treatment courses
01 3  ( 1 )
13 4 8  ( 3 4 )
2 or more 153 (15)
Recovered during treatment but relapsed 84 (8)
Duration of sick leave (n = 722)a
No sick leave 394 (54)
< 1 week 62 (9)
1-2 weeks 110 (15)
> 2 weeks 157 (22)
Delayed education (n = 460)b
No delay 311 (68)
< 1 semester 69 (15)
1 semester 44 (10)
> 1 semester 36 (8)
a Percent of persons estimated to be working (n = 722).
b Percent of persons estimated to be students (n = 460).BMC Infectious Diseases 2009, 9:206 http://www.biomedcentral.com/1471-2334/9/206
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Table 4: Abdominal symptoms two years after Giardia infection reported in a cohort of 1017 cases, associated with patient 
characteristics and factors during giardiasis.
Characteristics N Abdominal symptoms
No
N (%)
Unsure
N (%)
Yes
N (%)
Simple regression analysisa Multiple regression analysisb
OR p-value OR p-value 95% CI
Gender 0.029
Male 355 138 (39) 87 (25) 130 (37) 1.00 1.00
Female 622 222 (36) 141(23) 259 (42) 1.20 0.158 1.45 (1.04, 2.04)
Agec (years) 977 1.01 0.064 - Ns -
Abdominal problems before 2004 
leading to
Visiting doctor 119 35 (29) 39 (33) 45 (38) 1.13 0.516 - Ns -
Hospitalisation 17 4 (24) 8 (48) 5 (30) 1.04 0 925 - Ns -
Sick leave 18 7 (39) 8 (44) 3 (17) 0.62 0.286 - Ns -
Use of medication 40 12 (30) 16 (40) 12 (30) 0.94 0.826 Ns
Problems without seeking health 
care
94 30 (32) 26 (28) 38 (40) 1.13 0.539 - Ns -
No abdominal problems before 
2004
883 330 (37) 202 (23) 351 (40) 1.18 0.220 - Ns
Acute giardiasis
Diarrhoea 880 318 (36) 211 (24) 351 (40) 1.19 0.390 - Ns -
Abdominal pain 674 212 (32) 160 (24) 302 (45) 2.05 <0.001 - Ns -
Weight loss 529 187 (35) 128 (24) 214 (41) 1.10 0.411 - Ns -
Malaise 742 242 (33) 183 (25) 317 (43) 1.91 <0.001 - Ns -
Nausea 632 226 (36) 150 (24) 256 (41) 1.11 0.391 - Ns -
Foul smell 595 178 (30) 146 (25) 271 (46) 2.00 <0.001 - Ns
Bloating 645 176 (27) 158 (25) 311 (48) 3.20 <0.001 1.51 0.023 (1.06, 2.16)
Treatment refractory infectiond 28 7 (25) 6 (21) 15 (54) 1.78 0.117 3.08 0.030 (1.11, 8.53)
Treatment coursese <0.001
0 or 1 360 242 (67) 85 (24) 33 (9) 1.00 1.00
2 or more 237 99 (42) 69 (29) 69 (29) 3.23 <0.001 3.39 <0.001 (2.33, 4.94)
Recovered during course but 
relapsed
3 1 (33) 1 (33) 1 (33) 4.38 0.166 5.05 Ns (0.57, 45.11)
Not recovered 374 16 (4) 73 (20) 285 (76) 30.54 <0.001 32.81 <0.001 (21.67, 49.65)
Sick leavee Ns
No sick leave 387 162 (42) 85 (22) 140 (36) 1.00 1.00
< 1 week 61 20 (33) 19 (31) 22 (36) 1.21 0.460 - Ns -
1-2 weeks 105 41 (39) 32 (31) 32 (31) 0.95 0.806 - Ns -
> 2 weeks 153 43 (28) 27 (18) 83 (54) 2.04 <0.001 - Ns -
Not working 241 85 (35) 60 (25) 96 (40) 1.26 0.150 - Ns -
Delayed educatione 0.020
No delay 306 140 (46) 65 (21) 101 (33) 1.00 1.00
< 1 semester 67 25 (37) 15 (22) 27 (40) 1.40 0.175 1.06 Ns (0.60, 1.89)
1 semester 42 9 (21) 10 (24) 23 (55) 2.69 0.002 2.47 0.024 (1.13, 5.45)
> 1 semester 34 1 (3) 8 (24) 25 (74) 6.64 <0.001 3.50 0.013 (1.30, 9.38)
Not a student 379 141 (37) 91 (24) 147 (39) 1.36 0.031 3.14 Ns (0.80, 1.63)
Abbreviations: OR, odds ratio; Ns, not significant; CI, confidence interval.
a Simple ordinal logistic regression analysis (proportional odds model).
b Ordinal logistic regression analysis. Multiple regression analysis included all variables in the table. Missing values; n = 205.
c Age as continuous variable in the statistical analysis.
d All cases successfully treated with albendazole + metronidazole, paromomycin or quinacrine + metronidazole after 30 (mean) weeks duration of 
infection [11].
e Categorical variable in the statistical analysis including the categories shown in the table. Likelihood-ratio test (STATA).BMC Infectious Diseases 2009, 9:206 http://www.biomedcentral.com/1471-2334/9/206
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Table 5: Fatigue two years after Giardia infection reported in a cohort of 1017 cases, associated with patient characteristics and factors 
during giardiasis.
Characteristics N Fatigue
Not more 
than usual
N (%)
More than 
usual
N (%)
Much more 
than usual
N (%)
Simple regression 
analysisa
Multiple regression analysisb
OR P-value OR p-value 95% CI
Gender Ns
Male 338 199 (59) 107 (32) 32 (10) 1.00 1.00
Female 592 312 (53) 199 (34) 81 (14) 1.32 0.038 -
Agec (years) 930 1.02 <0.001 1.02 0.007 (1.01, 1.03)
Abdominal 
problems 
before 2004 
leading to
Visiting doctor 114 49 (43) 50 (44) 15 (13) 1.56 0.020 - Ns
Hospitalisation 14 4 (29) 8 (57) 2 (14) 2.21 0.113 - Ns
Sick leave 17 6 (35) 10 (59) 1 (6) 1.60 0.309 - Ns
Use of 
medication
35 15 (43) 18 (51) 2 (6) 1.31 0.414 - Ns
Problems 
without 
seeking health 
care
95 45 (47) 40 (42) 10 (11) 1.26 0.256 2.13 0.025 (1.10, 4.15)
No abdominal 
Problems 
before 2004
662 380 (57) 198 (30) 84 (13) 0.78 0.081 - Ns
Acute giardiasis
Diarrhoea 839 456 (54) 279 (33) 104 (12) 1.28 0.255 - Ns
Abdominal pain 646 322 (50) 236 (37) 88 (14) 1.95 <0.001 - Ns
Weight loss 506 255 (50) 180 (36) 71 (14) 1.50 0.002 - Ns
Malaise 714 334 (47) 277 (39) 103 (14) 5.03 <0.001 3.68 <0.001 (2.25, 6.01)
Nausea 604 302 (50) 215 (36) 87 (14) 1.81 <0.001 - Ns
Foul smell 580 290 (50) 201 (35) 89 (15) 1.80 <0.001 - Ns
Bloating 622 311 (50) 224 (36) 87 (14) 1.84 <0.001 - Ns
Treatment 
refractory infec-
tiond
29 13 (45) 11 (38) 5 (17) 1.52 0.236 - Ns
Treatment 
coursese
<0.001
0 or 1 326 249 (76) 68 (21) 9 (3) 1.00 1.00
2 or more 227 128 (56) 77 (34) 22 (10) 2.55 <0.001 1.98 0.002 (1.28, 3.07)
Recovered 
during course 
but relapsed
3 2 (67) 1 (33) 0 (0) 1.50 0.742 2.37 Ns (0.19, 29.08)
Not recovered 371 129 (35) 160 (43) 82 (22) 6.39 <0.001 6.20 <0.001 (4.16, 9.24)
Sick leavee 0.001
No sick leave 368 232 (63) 106 (29) 30 (8) 1.00 1.00
< 1 week 58 30 (52) 24 (41) 4 (7) 1.45 0.180 0.93 Ns (0.49, 1.77)
1-2 weeks 98 63 (64) 29 (30) 6 (6) 0.93 0.740 0.72 Ns (0.42, 1.23)
> 2 weeks 150 55 (37) 50 (33) 45 (30) 3.63 <0.001 2.26 <0.001 (1.45, 3.53)
Not working 232 125 (54) 84 (36) 23 (10) 1.42 0.035 1.08 Ns (0.71, 1.63)
Delayed educa-
tione
0.001BMC Infectious Diseases 2009, 9:206 http://www.biomedcentral.com/1471-2334/9/206
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types and clinical manifestations have shown different
results: Both genotype A and B have been responsible for
severe symptoms, with the genotype less prevalent in the
community responsible for more severe clinical manifes-
tation [35-38]. In Norway 11% of raw water samples con-
tains  Giardia  parasites in low concentrations, most
commonly genotype A, while the outbreak strain in Ber-
gen was assemblage B [39,40]. Previous studies from the
outbreak suggest that some sub-genotypes induced a
more severe infection [11,41], and one may speculate if
particular sub-genotypes lead to an immune reaction
responsible for protracted low-grade inflammation. Also
in IBS following infections other than giardiasis, toxicity
within species has been reported as a risk factor, as in
Campylobacter infection [18].
Age was significantly associated with fatigue as previously
reported from this cohort [8], which is in line with find-
ings in a Norwegian population study [42]. We did not
find any significant association between age and abdomi-
nal symptoms. Age >60 years was protective against PI-IBS
in one study [29], and one mechanism was suggested to
be that the gut in older subjects might be less reactive to
infection [43].
Female gender seemed to be a risk factor for both fatigue
and abdominal symptoms in some but not all analyses,
and this finding must therefore be interpreted with cau-
tion. An association between chronic fatigue and female
gender has been reported in other studies [13,42,44-46].
Female gender has also been associated with PI-IBS in
some reports; however, this association was no longer sig-
nificant when analyses were adjusted for psychological
disturbances [19,28,29,47].
Malaise during infection was associated with fatigue, and
bloating with abdominal symptoms. This may either indi-
cate recall bias influenced by symptoms present at the
time of reporting, or a real risk of complications if these
symptoms are prominent.
There was no association between previous abdominal
problems and post-infectious abdominal symptoms. The
finding that "previous abdominal problems without seek-
ing health care" was associated with fatigue should be
interpreted with caution since other factors measuring
previous abdominal problems were not associated. The
possible impact of recall bias on the outcome regarding
previous abdominal problems in this study may be less
since the questions were phrased as facts ("hospitalised"
etc) rather than symptoms.
Chronic Giardia infection may develop in 15% of patients
if not treated [4], and may be misdiagnosed as IBS due to
similar symptoms [48]. Giardia was found in 6.5% of IBS
cases in one study from Italy [49], and in a meta-analysis
from the Nordic countries, giardiasis was found in 3.0%
of the asymptomatic, and in 5.8% of the symptomatic,
population [50].
We have previously shown that all referred treatment
refractory cases after the Bergen outbreak eradicated the
parasite, evaluated by seven negative stool samples up to
four weeks after treatment [11]. In 25 Giardia negative
patients from this outbreak, treatment with metronida-
zole/albendazole or tetracycline/folic acid was not effec-
tive, and cryptic giardiasis was therefore excluded [51]. We
have also described that IBS persisted in patients after nor-
malisation of duodenal biopsies [17]. These reports sup-
port that chronic infection is not the cause of fatigue and
abdominal symptoms in this cohort.
A major strength of the study is the large number of cases,
and the high response rate. A limitation may be the risk of
over-reporting of symptoms since local authorities have
accepted to compensate any economical loss due to the
infection. Possible reporting bias due to limitations in the
questionnaire could have been reduced if validated meas-
ures of chronic fatigue and IBS had been used in a control-
led study. Also, the study lacks information on co-
morbidity and professional background. It is unclear
No delay 291 205 (70) 67 (23) 19 (7) 1.00 1.00
< 1 semester 66 31 (47) 30 (46) 5 (8) 2.34 0.002 1.79 0.049 (1.00, 3.19)
1 semester 39 13 (33) 17 (44) 9 (23) 4.64 <0.001 2.80 0.004 (1.39, 5.66)
> 1 semester 35 8 (23) 13 (37) 14 (40) 9.21 <0.001 3.88 <0.001 (1.82, 8.30)
Not a student 357 188 (53) 121 (34) 48 (13) 2.17 <0.001 1.51 0.033 (1.03, 2.21)
Abbreviations: OR, odds ratio; Ns, not significant.
a Simple ordinal logistic regression analysis (proportional odds model).
b Ordinal logistic regression analysis (proportional odds model). Multiple regression analysis included all variables in the table. Missing values; n = 
241
c Age as continuous variable in the statistical analysis.
d All cases successfully treated with albendazole + metronidazole, paromomycin or quinacrine + metronidazole after 30 (mean) weeks duration of 
infection [11].
e Categorical variable in the statistical analysis including the categories shown in the table. Likelihood-ratio test (STATA)
Table 5: Fatigue two years after Giardia infection reported in a cohort of 1017 cases, associated with patient characteristics and factors 
during giardiasis. (Continued)BMC Infectious Diseases 2009, 9:206 http://www.biomedcentral.com/1471-2334/9/206
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whether these limitations have influenced the outcome of
the study. On the other hand, the study was initiated by
clinicians after observing a substantial number of patients
with severe chronic fatigue and/or abdominal symptoms
after giardiasis, supporting that self reporting of symp-
toms associated with giardiasis in this cohort is consistent
with clinical observations.
Conclusions
Protracted and severe Giardia  infection, or possibly
inflammation, seems to be a risk factor for post-infectious
fatigue and abdominal symptoms two years after clearing
the parasites. These symptoms are often pronounced,
reduce quality of life and have economical implications in
the society. If the observed association is causal, shorten-
ing the duration of Giardia infection by early diagnosis
and treatment may be important also in order to reduce
the risk for such complications.
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